Novo Nordisk Eyes Approval For Potential First Oral GLP-1 Diabetes Pill In Young Patients

Novo Nordisk reports phase 3 data showing oral semaglutide reduced HbA1c in adolescents with type 2 diabetes and was well tolerated. Importance Rank: 1 read more

Go to News Site